{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/65736d39d32e730012c98919/690e0df36d62d4e03d70550d?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"uniQure Staggers at FDA, Recursion's Microglia Map, and Leadership Transitions","description":"<p>uniQure's “game changing” data announced in September, which showed significant slowing of Huntington’s disease (HD) progression in patients treated with its gene therapy candidate AMT-130, may not be enough to secure FDA approval. We also discuss Recursion's pivotal leadership transitions, as Najat Khan, PhD, chief R&amp;D officer and chief commercial officer, is set to take over as the company's CEO effective January 1. The AI drug developer has made big bets filling the biology data gap and recently announced a \"Google Map of the brain\" to advance neurodegenerative disease targets. In open-source AI for drug discovery, the release of the latest Boltz model, BoltzGen, advances the platform from structural predictions to the design of \"any\" therapeutic modality, all available for commercial use.&nbsp;</p><p>&nbsp;</p><p>Join <em>GEN</em> editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news. &nbsp;</p><p><br></p><p> &nbsp;</p><p>Listed below are links to the <em>GEN</em> stories referenced in this episode of <em>Touching Base</em>: &nbsp;</p><p>&nbsp;</p><p><a href=\"https://www.genengnews.com/topics/genome-editing/uniqure-staggers-as-fda-questions-data-for-huntingtons-gene-therapy-candidate/\" rel=\"noopener noreferrer\" target=\"_blank\">uniQure Staggers as FDA Questions Data for Huntington’s Gene Therapy Candidate</a>&nbsp;</p><p>By Alex Philippidis, <em>GEN Edge</em>, November 3, 2025&nbsp;</p><p> &nbsp;</p><p><a href=\"https://www.genengnews.com/topics/translational-medicine/stockwatch-uniqure-shares-reach-five-year-high-on-game-changing-huntingtons-data/\" rel=\"noopener noreferrer\" target=\"_blank\">StockWatch: uniQure Shares Reach Five-Year High on “Game Changing” Huntington’s Data</a>&nbsp;</p><p>Alex Philippidis<em>, GEN Edge,</em> September 28, 2025&nbsp;</p><p>&nbsp;</p><p><a href=\"https://www.genengnews.com/topics/genome-editing/gene-therapy-significantly-slows-huntington-disease-progression/\" rel=\"noopener noreferrer\" target=\"_blank\">Gene Therapy Significantly Slows Huntington Disease Progression</a>&nbsp;</p><p><em>GEN,</em> September 24, 2025&nbsp;</p><p>&nbsp;</p><p><a href=\"https://www.genengnews.com/topics/drug-discovery/recursion-roche-unveil-microglia-map-of-neuro-disease-targets/\" rel=\"noopener noreferrer\" target=\"_blank\">Recursion, Roche Unveil Microglia Map of Neuro Disease Targets</a>&nbsp;</p><p>By Alex Philippidis, <em>GEN Edge</em>, October 29, 2025&nbsp;</p><p>&nbsp;</p><p><a href=\"https://www.genengnews.com/topics/artificial-intelligence/boltzgen-democratizes-ai-therapeutic-design-expands-druggable-universe/\" rel=\"noopener noreferrer\" target=\"_blank\">BoltzGen Democratizes AI Therapeutic Design, Expands Druggable Universe</a>&nbsp;</p><p>By Fay Lin, PhD, <em>GEN</em>, October 27, 2025&nbsp;</p><p>&nbsp;</p><p><a href=\"https://www.genengnews.com/multimedia/summits/the-state-of-ai-in-drug-discovery-2025/\" rel=\"noopener noreferrer\" target=\"_blank\">The State of AI in Drug Discovery On Demand</a> &nbsp;</p><p> &nbsp;</p><p><a href=\"https://www.genengnews.com/category/multimedia/podcasts/touching-base/\" rel=\"noopener noreferrer\" target=\"_blank\">Touching Base Podcast</a> &nbsp;</p><p>Hosted by Corinna Singleman, PhD &nbsp;</p><p>&nbsp;</p><p><a href=\"https://www.insideprecisionmedicine.com/category/multimedia/podcasts/\" rel=\"noopener noreferrer\" target=\"_blank\">Behind the Breakthroughs</a> &nbsp;</p><p>Hosted by Jonathan D. Grinstein, PhD &nbsp;</p><p> &nbsp;</p>","author_name":"Genetic Engineering & Biotechnology News (GEN)"}